| Literature DB >> 29447419 |
Phyllis Butow, Louise Sharpe, Belinda Thewes, Jane Turner, Jemma Gilchrist, Jane Beith.
Abstract
With increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients' quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status. Oncologists can assess and screen for FCR using validated measures; provide adequate information about prognosis, signs and symptoms of recurrence, and behavioral strategies for risk reduction and follow-up; and warn patients and families that FCR may be an issue in survivorship. It is important to normalize FCR and encourage patients to discuss it if it is a concern. Patients with severe FCR should be referred to psycho-oncology staff, who can apply some of the novel psychotherapeutic interventions that have emerged to address this condition.Entities:
Mesh:
Year: 2018 PMID: 29447419
Source DB: PubMed Journal: Oncology (Williston Park) ISSN: 0890-9091 Impact factor: 2.990